Research on Liposomal Irinotecan in Combination with 5-FU/LV for Metastatic Pancreatic Ductal Adenocarcinoma  

作　　者：Wang Wenjun Wang Yaoling Huang Zhe 

机构地区：[1]School of Business Administration,Shenyang Pharmaceutical University,Shenyang 110016,China [2]China National Health Development Research Center,National Health Commission,Beijing 100044,China

出　　处：《Asian Journal of Social Pharmacy》2023年第2期128-136,共9页亚洲社会药学（英文）

摘　　要：Objective To systematically review the published clinical and economic research on liposomal irinotecan in combination with 5-FU/LV for metastatic pancreatic ductal adenocarcinoma(mPDAC)at home and abroad.Methods PubMed,Cochrane Library,Embase,CBM,CNKI,Wan Fang data,CRD database and health technology assessment official websites were searched to collect clinical and economic studies on liposomal irinotecan for mPDAC.Results and Conclusion Nine clinical studies and four economic studies were included.The result of clinical studies showed that liposomal irinotecan in combination with 5-FU/LV could extend survival with good drug compliance in patients with mPDAC who progressed on prior gemcitabine-based therapy.This agent represented a new treatment option for second-line chemotherapy in these patients.The results of the economic evaluations failed to reach a consistent conclusion due to different economic levels in various countries.

关 键 词：liposomal irinotecan metastatic pancreatic ductal adenocarcinoma(mPDAC) CHEMOTHERAPY clinical research economic evaluation 

分 类 号：R735.9[医药卫生—肿瘤]